EGFR and non-small cell lung carcinoma: This case highlights the clinical relevance of RET fusions as a mechanism of acquired resistance to osimertinib in EGFR-mutant NSCLC and supports the use of combination therapy with selpercatinib and osimertinib as a rational and tolerable treatment strategy.